Biological Factors Linking ApoE ε4 Variant and Severe COVID-19 Jameel Inal Letter to the Editor 02 October 2020 Article: 70
Structural Basis for Vital Function and Malfunction of Serum Amyloid A: an Acute-Phase Protein that Wears Hydrophobicity on Its Sleeve Olga Gursky Vascular Biology (J. Hamilton, Section Editor) 24 September 2020 Article: 69
Therapeutic Apheresis for Management of Lp(a) Hyperlipoproteinemia Sergei N. PokrovskyOlga I. AfanasievaMarat V. Ezhov Nonstatin Drugs (M. Vrablik, Section Editor) 18 September 2020 Article: 68
The Role of Nutraceuticals in the Optimization of Lipid-Lowering Therapy in High-Risk Patients with Dyslipidaemia Peter E. PensonMaciej Banach Nonstatin Drugs (M. Vrablik, Section Editor) Open access 18 September 2020 Article: 67
Targeting Inflammation to Reduce Residual Cardiovascular Risk Oluremi N. AjalaBrendan M. Everett Nonstatin Drugs (M. Vrablik, Section Editor) 03 September 2020 Article: 66
Gender Differences in Residual Risk Factors for Major Adverse Cardiovascular Events Following ACS and How to Bridge the Gap Olivia ManfriniEdina CenkoRaffaele Bugiardini Women and Ischemic Heart Disease (P. Kohli, Section Editor) 03 September 2020 Article: 65
The Knowns and Unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia Jing PangDick C. ChanGerald F. Watts Statin Drugs (R. Ceska, Section Editor) 01 September 2020 Article: 64
Familial Chylomicronemia Syndrome (FCS): Recent Data on Diagnosis and Treatment Antonio GalloSophie BéliardEric Bruckert Statin Drugs (R Ceska, Section Editor) 27 August 2020 Article: 63